May 22, 2024 03:12 PM EDT
Deals
Cell/Gene Tx
Manufacturing

Mer­ck KGaA makes $600M bet to boost man­u­fac­tur­ing for vi­ral vec­tors

Max Gelman

Senior Editor

Mer­ck KGaA an­nounced Wednes­day that it is ac­quir­ing Mirus Bio, a start­up that de­vel­ops trans­fec­tion reagents for vi­ral cell and gene ther­a­pies, for $600 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pe­ter Marks sin­gle-hand­ed­ly ap­proved Sarep­ta’s gene ther­a­py — what does that mean for every­one else?

Three of Ver­tex’s islet cell ther­a­py pa­tients go in­sulin-in­de­pen­dent

Lil­ly’s Zep­bound re­solves sleep ap­nea in obese pa­tients, fur­ther­ing case for la­bel ex­pan­sion

Bris­tol My­ers wins ap­proval for KRAS drug Kraza­ti in col­orec­tal can­cer

Sci­en­tists just dis­cov­ered a new ge­net­ic clue for de­lay­ing Alzheimer’s dis­ease. It’s al­ready in­spir­ing drug ...

The End­points Slack in­ter­view: Saji Wick­ra­masekara on where AI miss­es the mark — and what's next for Bench­ling

A service from the Financial Times